MedPath

Human Cardiac Mitochondria in Acute Endocarditis and Obesity

Conditions
Endocarditis
Obesity
Interventions
Other: Endocarditis
Other: Obese vs. control
Registration Number
NCT03690076
Lead Sponsor
University Hospital, Clermont-Ferrand
Brief Summary

Data about human cardiac mitochondria are cruelly lacking in the literature. However, damages of the activity of these organelles are often the source of abnormal cardiac function in several pathologies. The purpose of this study is to develop a model of purified human cardiac mitochondria, to verify the purity of these organelles and to validate the authenticity of their function in acute endocarditis and obesity, two situations known to alter their activity. Animal studies have shown that microbial infection reduced mitochondrial metabolism whereas obesity increases it. The investigator's hypotheses are the following: 1) acute endocarditis, a form of cardiac microbial infection, reduces the function of human cardiac mitochondria; 2) obesity (body mass index \> 30) activates the metabolism of human cardiac mitochondria.

Detailed Description

3 groups of patients:

* Controls: patients with normal weight (23 \< BMI \< 27) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis

* Endocarditis: patients with normal weight (23 \< BMI \< 27) carriers of endocarditis with surgery indication

* Obese: obese patients (BMI \> 30) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis

Comparisons studied:

* Controls vs. endocarditis

* Controls vs. obese patients

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
90
Inclusion Criteria
  • For the controls : adult patients with normal body weight (23 < BMI < 27) necessitating a cardiac surgery with sternotomy and extracorporeal circulation for myocardial revascularization or valve replacement
  • For endocarditis : adult patients with normal body weight (23 < BMI < 27) and endocarditis of bacterial origin necessitating a cardiac surgery with sternotomy and extracorporeal circulation in order to cure a major valve regurgitation or vegetation with higher size than 15 mm with embolic risk
  • For obese patients: adult patients with high body weight (BMI > 30 and waist to hip ration > or = 1 for men and 0.85 for women) necessitating a cardiac surgery with sternotomy and extracorporeal circulation for myocardial revascularization or valve replacement

For all the patients:

  • Ability to furnish an enlightened agreement
  • Menbership of the French social security insurance
Exclusion Criteria
  • Criteria linked to the surgery:
  • Surgery of pressing emergency
  • Aortic dissection
  • Redux surgery

Criteria linked to the patient:

  • Protocol refusal
  • Protected adult patients
  • Previous psychiatric pathology including known addiction states
  • Physical or intellectual inability
  • Preexisting pathologies such as respiratory failure
  • Cardiac failure (ejection fraction < 30% pulmonary hypertenstion > 80 mmHg); aortic counterpulsation; pre-operatory cardiogenic shock
  • Severe acute or chronic renal failure with creatinine clearance < 40 ml/min
  • Inherited dyslipidemia
  • Previous cardiac or thoracic surgery with pericardium opening
  • Severe hepatic failure and severe chronic hepatic pathologies
  • Evolving neoplasia
  • Patients with long course corticoid treatment and with inflammatory diseases
  • Patients with double anti-platelet treatment not stopped 48h before the surgery
  • Protected people not involved in the study: pregnant women, nursing women, guardianship, deprived of liberty,

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
EndocarditisEndocarditispatients with normal weight (23 \< BMI \< 27) carriers of endocarditis with surgery indication
ControlEndocarditispatients with normal weight (23 \< BMI \< 27) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
ObeseObese vs. controlobese patients (BMI \> 30 with waist to hip ratio \> or = 1 in men and 0.85 in women) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
Primary Outcome Measures
NameTimeMethod
Mitochondrial functionat day 1 (Moment of the surgery)

Measurement of oxidative phosphorylation and reactive oxygen species release in isolated human cardiac mitochondria

Secondary Outcome Measures
NameTimeMethod
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0at day (+30)

Exercise testing

Patient follow-up during the hospital staymorbi-mortality at day (+90)

quantity of time (h) spent by the patient during the stay in reanimation

Morbi-mortalitymeasurement during the post-operative 90 days

rates of deaths and complications (cardiac, renal, hepatic, etc.) during the 90 days following the surgery for all the patients

walk testat the moment of inclusion in the study (day (-10-5)) and of the end of hospitalization (day +7+10)

6-minutes walk test

body composition1 day before the surgery

determination of lean masses by impedance-metry

Electrocardiogram : Detections of the rates in events per min of arrhythmiasat days (-10-5), (+7+10), (+30) and (+90)

Detections of the rates in events per min of arrhythmias (existence of P wave followed by a QRS complex) and atrio-ventricular blocks in all the patients

Membrane lipid compositionat day 1 (at the day of surgery)

Fatty acid composition of plasma lipids

Markers of oxidative stress in the plasmaat days (0) and (+30) for the plasma and day (0) for the myocardium

Markers of the oxidative stress in the plasma (amounts of thiol groups and TBARS, activities of SOD, catalase, glutathione peroxidase, ratio between the amounts of GSH and GSSG) and in the myocardium (whole myocardium: ratio between the activities of aconitase and fumarase, amount of protein carbonylation; isolated mitochondria: amount of nitrosylated proteins)

Concentrations of inflammation cytokines in the plasmaat days (-10-5), (0), (+1), (+2), (+7) and (+90)

Inflammatory cytokines in the plasma (IL-6, IL-1b, TNF-a, fibrinogen, CRP and pro-calcitonin

Semi-quantitative analysis of the amounts of approximatively 6000 molecules in the plasma by metabolomic and lipidomic techniquesat days (0) and (+30)

Studies performed in the plasma by a U.S. private society (Metabolon)

Trial Locations

Locations (1)

Chu Clermont-Ferrand

🇫🇷

Clermont-Ferrand, France

© Copyright 2025. All Rights Reserved by MedPath